Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

Lead Sponsor:

Celon Pharma SA

Collaborating Sponsors:

National Center for Research and Development, Poland

Conditions:

Schizophrenia

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of sch...

Detailed Description

This is a double-blind, randomized, placebo controlled, parallel group, dose ranging study to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (phosphodiesterase 10A...

Eligibility Criteria

Inclusion

  • The patient has a primary diagnosis of schizophrenia confirmed by clinical interview \[SCID-5-CT\].
  • Male or female patient aged 18 to 65, inclusive, at Screening.
  • The patient's with exacerbation of psychotic symptoms
  • The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline
  • The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline
  • The patient of childbearing potential willing to use acceptable forms of contraception.
  • The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline
  • The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.
  • The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.

Exclusion

  • The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
  • Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
  • The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
  • The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
  • The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
  • The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
  • The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
  • The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
  • The patient has chronic movement disorder that may interfere with the interpretation of study results.
  • The patient has any existing or previous history of cancer or has newly diagnosed diabetes.
  • The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.
  • The patient is considered to be treatment resistant. .
  • The patient has received electroconvulsive therapy.
  • The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.

Key Trial Info

Start Date :

May 19 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 19 2024

Estimated Enrollment :

189 Patients enrolled

Trial Details

Trial ID

NCT05278156

Start Date

May 19 2021

End Date

June 19 2024

Last Update

September 10 2025

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Department of Psychiatry and Psychotheraapy of Semmelweis University

Budapest, Hungary, H-1083

2

Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy

Budapest, Hungary, H-1085

3

Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital

Győr, Hungary, H-9024

4

Bács-Kiskun County Teaching Hospital Kalocsa Holy Cross Hospital

Kalocsa, Hungary, H-6300